Market Overview:
The global pituitary ACTH hypersecretion drug market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The market growth can be attributed to factors such as the increasing prevalence of pituitary tumors, rising awareness about the treatment options for pituitary ACTH hypersecretion, and growing demand for novel therapies. The global pituitary ACTH hypersecretion drug market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into AT-814, ATR-101, BIM-23A758, COR-005 CORT-125134 ISIS-GCCRRx Others. On the basis of application,the market is segmented into clinic hospital others.
Product Definition:
Pituitary ACTH Hypersecretion Drug is a medication used to treat pituitary ACTH hypersecretion, a condition in which the body produces too much adrenocorticotropic hormone (ACTH). Pituitary ACTH Hypersecretion Drug may also be used for purposes not listed in this medication guide.
AT-814:
AT-814, also known as Dacogen, is a drug that increases the activity of the pituitary adenylate cyclase. It was developed by Actavis plc and Wockhardt Ltd to treat Cushing syndrome and acromegaly. The drug received FDA approval in December 2003 for Cushing's disease (as well as for gigantism) and in January 2004 for acromegaly.
ATR-101:
ATR-101 is a drug developed by Actavis plc. It is an investigational anti-Cushing's syndrome drug and has been designated as a fast track therapy by the FDA. The primary indication for which this drug has been tested thus far is Cushing's syndrome, however, it was found to have significant effects on other endocrine disorders as well such as adrenal insufficiency and hypopituitarism resulting from any medical condition including cancer.
Application Insights:
The others segment held the largest share of the global pituitary ACTH hypersecretion drug market in 2017. This is due to a high incidence of Cushing¢â‚¬â„¢s disease and/or non-classical hypercortisolism that occurs in patients from various ethnic groups, especially those originating from South Asian and Middle Eastern countries.
Non-classical or atypical hypercortisolism is an endocrine disorder characterized by excessive secretion of cortisol at night time as compared to daytime, leading to insomnia and other sleep disorders. The treatment includes replacement therapy with a synthetic or natural glucocorticoid hormone which can be obtained via oral tablets, injections or patches depending upon its type.
Regional Analysis:
North America dominated the global market in 2017. The presence of key players, favorable reimbursement scenario, and increasing awareness levels are some of the factors responsible for its dominance. In addition, approval and launch of new pituitary ACTH hypersecretion drugs by manufacturers such as Pfizer Inc.; Novartis AG; Merck & Co., Inc.; Takeda Pharmaceuticals International BV; Eisai Co., Ltd.; F. Hoffmann-La Roche AG; Allergan PLC; Actavis plc; and Otsuka Pharmaceutical Co., Ltd have contributed to its growth over the past few years.
Asia Pacific is expected to be one of fastest growing regions owing to rising disposable income coupled with improving healthcare infrastructure in emerging countries such as China and India which are major consumers for this medication market like Japan.
Growth Factors:
- Increasing incidence of pituitary adenomas
- Growing demand for novel therapies for the treatment of pituitary tumors
- Rising awareness about the benefits of early diagnosis and treatment of pituitary tumors
- Technological advancements in diagnostic and therapeutic procedures for pituitary tumors
- Availability of affordable and innovative treatments options for patients with pituitary ACTH hypersecretion
Scope Of The Report
Report Attributes
Report Details
Report Title
Pituitary ACTH Hypersecretion Drug Market Research Report
By Type
AT-814, ATR-101, BIM-23A758, COR-005, CORT-125134, ISIS-GCCRRx, Others
By Application
Clinic, Hospital, Others
By Companies
Alder Biopharmaceuticals Inc., Corcept Therapeutics Incorporated, Cortendo AB, Cyclacel Pharmaceuticals, Inc., ElexoPharm GmbH, Ipsen S.A., Isis Pharmaceuticals, Inc., Novartis AG, Orphagen Pharmaceuticals, Inc., Pfizer Inc.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
240
Number of Tables & Figures
168
Customization Available
Yes, the report can be customized as per your need.
Global Pituitary ACTH Hypersecretion Drug Market Report Segments:
The global Pituitary ACTH Hypersecretion Drug market is segmented on the basis of:
Types
AT-814, ATR-101, BIM-23A758, COR-005, CORT-125134, ISIS-GCCRRx, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Clinic, Hospital, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Alder Biopharmaceuticals Inc.
- Corcept Therapeutics Incorporated
- Cortendo AB
- Cyclacel Pharmaceuticals, Inc.
- ElexoPharm GmbH
- Ipsen S.A.
- Isis Pharmaceuticals, Inc.
- Novartis AG
- Orphagen Pharmaceuticals, Inc.
- Pfizer Inc.
Highlights of The Pituitary ACTH Hypersecretion Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- AT-814
- ATR-101
- BIM-23A758
- COR-005
- CORT-125134
- ISIS-GCCRRx
- Others
- By Application:
- Clinic
- Hospital
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Pituitary ACTH Hypersecretion Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Pituitary ACTH hypersecretion drug is a medication that helps to increase the production of the hormone ACTH in the pituitary gland. This can be used to treat conditions such as Cushing's syndrome, primary adrenal insufficiency, and Addison's disease.
Some of the major companies in the pituitary acth hypersecretion drug market are Alder Biopharmaceuticals Inc., Corcept Therapeutics Incorporated, Cortendo AB, Cyclacel Pharmaceuticals, Inc., ElexoPharm GmbH, Ipsen S.A., Isis Pharmaceuticals, Inc., Novartis AG, Orphagen Pharmaceuticals, Inc., Pfizer Inc..
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Pituitary ACTH Hypersecretion Drug Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Pituitary ACTH Hypersecretion Drug Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Pituitary ACTH Hypersecretion Drug Market - Supply Chain
4.5. Global Pituitary ACTH Hypersecretion Drug Market Forecast
4.5.1. Pituitary ACTH Hypersecretion Drug Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Pituitary ACTH Hypersecretion Drug Market Size (000 Units) and Y-o-Y Growth
4.5.3. Pituitary ACTH Hypersecretion Drug Market Absolute $ Opportunity
5. Global Pituitary ACTH Hypersecretion Drug Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Pituitary ACTH Hypersecretion Drug Market Size and Volume Forecast by Type
5.3.1. AT-814
5.3.2. ATR-101
5.3.3. BIM-23A758
5.3.4. COR-005
5.3.5. CORT-125134
5.3.6. ISIS-GCCRRx
5.3.7. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Pituitary ACTH Hypersecretion Drug Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Pituitary ACTH Hypersecretion Drug Market Size and Volume Forecast by Application
6.3.1. Clinic
6.3.2. Hospital
6.3.3. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Pituitary ACTH Hypersecretion Drug Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Pituitary ACTH Hypersecretion Drug Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Pituitary ACTH Hypersecretion Drug Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Pituitary ACTH Hypersecretion Drug Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Pituitary ACTH Hypersecretion Drug Demand Share Forecast, 2019-2026
9. North America Pituitary ACTH Hypersecretion Drug Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Pituitary ACTH Hypersecretion Drug Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Pituitary ACTH Hypersecretion Drug Market Size and Volume Forecast by Application
9.4.1. Clinic
9.4.2. Hospital
9.4.3. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Pituitary ACTH Hypersecretion Drug Market Size and Volume Forecast by Type
9.7.1. AT-814
9.7.2. ATR-101
9.7.3. BIM-23A758
9.7.4. COR-005
9.7.5. CORT-125134
9.7.6. ISIS-GCCRRx
9.7.7. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Pituitary ACTH Hypersecretion Drug Demand Share Forecast, 2019-2026
10. Latin America Pituitary ACTH Hypersecretion Drug Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Pituitary ACTH Hypersecretion Drug Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Pituitary ACTH Hypersecretion Drug Market Size and Volume Forecast by Application
10.4.1. Clinic
10.4.2. Hospital
10.4.3. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Pituitary ACTH Hypersecretion Drug Market Size and Volume Forecast by Type
10.7.1. AT-814
10.7.2. ATR-101
10.7.3. BIM-23A758
10.7.4. COR-005
10.7.5. CORT-125134
10.7.6. ISIS-GCCRRx
10.7.7. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Pituitary ACTH Hypersecretion Drug Demand Share Forecast, 2019-2026
11. Europe Pituitary ACTH Hypersecretion Drug Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Pituitary ACTH Hypersecretion Drug Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Pituitary ACTH Hypersecretion Drug Market Size and Volume Forecast by Application
11.4.1. Clinic
11.4.2. Hospital
11.4.3. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Pituitary ACTH Hypersecretion Drug Market Size and Volume Forecast by Type
11.7.1. AT-814
11.7.2. ATR-101
11.7.3. BIM-23A758
11.7.4. COR-005
11.7.5. CORT-125134
11.7.6. ISIS-GCCRRx
11.7.7. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Pituitary ACTH Hypersecretion Drug Demand Share, 2019-2026
12. Asia Pacific Pituitary ACTH Hypersecretion Drug Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Pituitary ACTH Hypersecretion Drug Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Pituitary ACTH Hypersecretion Drug Market Size and Volume Forecast by Application
12.4.1. Clinic
12.4.2. Hospital
12.4.3. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Pituitary ACTH Hypersecretion Drug Market Size and Volume Forecast by Type
12.7.1. AT-814
12.7.2. ATR-101
12.7.3. BIM-23A758
12.7.4. COR-005
12.7.5. CORT-125134
12.7.6. ISIS-GCCRRx
12.7.7. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Pituitary ACTH Hypersecretion Drug Demand Share, 2019-2026
13. Middle East & Africa Pituitary ACTH Hypersecretion Drug Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Pituitary ACTH Hypersecretion Drug Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Pituitary ACTH Hypersecretion Drug Market Size and Volume Forecast by Application
13.4.1. Clinic
13.4.2. Hospital
13.4.3. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Pituitary ACTH Hypersecretion Drug Market Size and Volume Forecast by Type
13.7.1. AT-814
13.7.2. ATR-101
13.7.3. BIM-23A758
13.7.4. COR-005
13.7.5. CORT-125134
13.7.6. ISIS-GCCRRx
13.7.7. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Pituitary ACTH Hypersecretion Drug Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Pituitary ACTH Hypersecretion Drug Market: Market Share Analysis
14.2. Pituitary ACTH Hypersecretion Drug Distributors and Customers
14.3. Pituitary ACTH Hypersecretion Drug Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Alder Biopharmaceuticals Inc.
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Corcept Therapeutics Incorporated
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Cortendo AB
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Cyclacel Pharmaceuticals, Inc.
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. ElexoPharm GmbH
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Ipsen S.A.
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Isis Pharmaceuticals, Inc.
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Novartis AG
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Orphagen Pharmaceuticals, Inc.
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Pfizer Inc.
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
